BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Singapore's Respiree receives regulatory approval for paediatric expansion of cardio-respiratory wearable

27 February 2025 | News

Sets its sights on securing additional regulatory approvals in other APAC regions

Singapore-based health tech startup Respiree has received clearance from the Health Sciences Authority (HSA) to extend its RS001 cardio-respiratory wearable to paediatric populations. This clearance also enables the extension of Respiree's software platform, introducing enterprise-grade pathway management services and EHR interoperability which further enhances its innovative healthcare solutions.

The RS001 is a wearable device that directly measures cardio-respiratory data, now expanded to serve both adult and paediatric populations. This innovative wearable collects vital data through sensors, transmitting it to a cellular hub, which then visualises the information on a user-friendly, connected dashboard.

Respiree's new dashboard software solution now includes integrated pathway management services, empowering physicians to deliver personalised care through advanced monitoring capabilities in the patient's home-use mobile application. Key features include: automated alerts setup and automated symptom questionnaire generation, seamless integration with Electronic Health Records (EHR) systems and enhanced interoperability through external API plugins.

With the expanded HSA clearance, Respiree sets its sights on securing additional regulatory approvals in other APAC regions, including the USA, within the next few months. Furthermore, Respiree plans to pursue clearances for its AI-powered Software-as-a-Medical-Device (SaMD), which will seamlessly integrate into its existing enterprise solution, bolstering its capabilities and impact on patients' lives.

Respiree is CE marked and has received regulatory clearances from the Therapeutic Goods Administration and the United States Food and Drug Administration (FDA).